Introduction

Alzheimer’s disease (AD) is a neurodegenerative disorder (1) that leads to progressive cognitive dysfunction (2–4) and affects different areas of the brain such as the amygdala, entorhinal cortex, and hippocampus (3, 5). The hippocampus, a brain area critical for learning and memory, is a vulnerable and plastic brain structure that is damaged at early stages of AD (6–8). The neuropathology of AD is characterised by extracellular deposits of β-amyloid (Aβ) plaques within senile plaques, intracellular neurofibrillary tangles of tau protein (NFTs) and neurodegeneration (9–11). Accumulation of Aβ plaques in the hippocampus lead to synaptic degeneration (12–14), neuronal apoptosis (15) and cognitive impairment (16, 17).

Abstract

Introduction: Intracerebroventricular administration of streptozotocin (icv-STZ) induced apoptosis changes in neurons similar to Alzheimer’s disease. The serotonergic system via its receptor involved in survival of neurons. The present study examined the ability of selective 5-HT1A receptor antagonist (NAD-299) and 5-HT2A receptor agonist (TCB-2) to attenuate the apoptosis caused by the icv-STZ in the rat.

Methods: The icv-STZ (3 mg/kg, 10 μL, twice) induced neuronal loss in the hippocampus of adult male rats. Animals were divided into naïve control, sham-operated, STZ+saline (1 μL, icv), STZ+NAD-299 (5 μg/μL, icv), STZ+TCB-2 (5 μg/μL, icv), and STZ+NAD-299+TCB-2 (5 μg/μL of any agent, icv) groups. Following the 35 days’ treatment period, neuronal apoptosis was detected using the Tunnel. Cells with morphological features of apoptotic cell were contended by microscopy.

Results: TCB-2 and NAD-299 administration decreased number of apoptotic neurons in the treatment group compared with the STZ group. Combined treatment of STZ rat with NAD+TCB more decreased number of apoptotic cells in compare to TCB-2 or NAD-299 treated STZ groups.

Conclusion: Treatment with 5-HT1A receptor antagonist or 5-HT2A receptor agonist diminished apoptosis. The beneficial effect of 5HT1A receptor inhibition was potentiated with activation of 5-HT2A receptor in prevention of apoptosis in hippocampus.

Keywords: streptozotocin, apoptosis, hippocampus, 5-HT1A receptor, 5-HT2A receptor, rat
Intracerebroventricular administration of streptozotocin (icv-STZ) is one of the animal models of AD (18–20). The local injection of STZ, a glucosamine derivative of nitrosourea, at a sub-diabetogenic dose makes similar pathology to AD such as aggregation of Aβ peptides (21, 22), tau hyperphosphorylation, impairment of brain glucose transporters of neurons (23) and increased neuronal death rate (20, 24–26). Apoptosis is a process of programmed cell death (21) and is a basic physiologic process contributing to the maintenance of cellular homeostasis (14, 19, 27, 28). Apoptosis is characterised by cytoplasmic membrane blebbing, cell shrinkage, chromatin condensation and nuclear DNA fragmentation (21, 29). A large number of apoptotic cells can be found in AD tissue (30). Mutations in AD causative genes such as amyloid precursor protein (APP), Presenilin-1 (PSEN1) and Presenilin-2 (PSEN2), increase Aβ peptide (31). In AD, there are several stimuli for apoptosis including reactive oxygen species, accumulation of Aβ (30), mitochondrial dysfunction and DNA damage (31).

Several neurotransmitter systems affected by AD including the acetyl choline, gamma-aminobutyric acid (GABA), serotonin and norepinephrine (2, 3, 32). Serotonin (5-hydroxytryptamine; 5-HT) is a multifunctional bioamine acting as a neurotransmitter and a neuromodulator with a particular presence in the hippocampus (33, 34). 5-HT has multiple functions in the mammalian central nervous system such as anxiety, memory, nociception, reward and addiction (35–37). These effects are mediated through seven types of 5-HTR (38). Seven families of 5-hydroxytryptamine receptors and subtypes (5-HT1A–1E, 5-HT2A–2C, 5-HT3A–3C, 5-HT4, 5-HT6, and 5-HT7) have been identified (39). All 5-HTR are G-protein-coupled receptors (GPCRs) with the exception of 5-HT3, which is a ligand-gated cation channel (40).

The highest density of the 5-HT1AR was found in areas important for learning and memory, such as the frontal cortex, hippocampus and septum (41). The 5-HT1AR is to stimulate cell proliferation, differentiation and apoptosis (42). It has been reported that the 5-HT1AR induces apoptosis in CHO cells (43). Several studies show that stimulation of postsynaptic 5-HT1AR in the dorsal raphe counteracts deficit in learning in naive rats (44), while 5-HT1AR antagonists can enhance cholinergic and/ or glutamatergic transmission and improve cognitive functions in various animal models of cognitive dysfunction (45). Over-expression of 5-HT1AR on a rat model of AD was demonstrated (46).

The 5-HT2A receptors are remarkably expressed in the hippocampus (33). It has been reported that 5-HT2AR agonists improved learning and memory impairments, while 5-HT2AR antagonists have anti-psychotic and anti-depressant properties (47). Recently, it was found that 5-HT1AR blockade and 5-HT2AR activation improved cognitive dysfunction in icv-STZ-treated rats (48). However, data regarding 5-HT1AR inhibition and 5-HT2AR activation in programme cell dead in AD rat is not available.

The previous study used Nissl staining in order to quantify the neuronal loss (48). The Nissl staining show nucleic acid content of cells (49). Neurons have DNA in the nuclei and RNA highly concentrated in rough endoplasmic reticulum and ribosomes (Nissl substance) (50) that stained with cresyl violet in this method (51). Due to Nissl staining technique is based on the binding of basic dye with the nucleic acid content of cells (50), it is not a specially distinguished nuclei of dead neuron (52). Terminal Deoxy nucleotidyl Transferase-Mediated dUTP Nick-End Labeling (TUNEL) staining is a suitable method for detecting DNA fragments of nuclei (53). Therefore, Tunnel is a very useful method to study the nuclei of neurons, and understand the apoptotic neurones of the brain area. The aim of this study was to determine the chronic effect of 5-HT1AR antagonist and 5-HT2AR agonist, on the rate of apoptosis in the hippocampus area in a rat model of AD.

Materials and Methods

Animals

Adult male Wistar rats (250 g–300 g) were obtained from the animal house of Hamadan University of Medical Sciences. All animals were housed in a room with temperatures ranging from 20 °C–24 °C and lights maintained on a 12:12 light: dark cycle. Rats were allowed to acclimate for one week prior to the study. Water and food were available ad libitum. All experiments were approved by the research and ethics committees of the Hamadan University of Medical Sciences (IR.UMSHA.REC.1395.547) and were performed according to the Guide for Care and Use of Laboratory Animals published by the United States National Institutes of Health (NIH Publication No. 85-23, revised 1985).
**Chemicals**

STZ was purchased from Santacruz Company (CA, USA). NAD-299, [(R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide hydrogen (2R,3R)-tartrate monohydrate; AZD7371] and TCB-2 [(7R)-3-bromo-2,5-dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-yl] methanamine] were purchased from Tocris Bioscience Company (Bristol, UK). NAD-299 and TCB-2 were dissolved in dimethyl sulfoxide (DMSO) and STZ was dissolved in normal saline.

**Study Design**

The rats were divided randomly into the following six groups (n = 5 rats in each group): (i) control group, which did not undergo operation or treatment; (ii) sham group, which received 10 μL of vehicle via icv injection during operation and subsequently received 1 μL of vehicle for treatment; (iii) AD group, which received STZ (3 mg/kg, 10 μL) via intracerebroventricular (icv) injection during operation and subsequently received 1 μL of vehicle treatment for 35 days; (iv) AD+NAD-299-299 group, which received STZ via icv injection during operation and subsequently received NAD-299 (selective 5-HT1A R antagonist, 5 μg/μL); v) AD+TCB-2 group, which received STZ via icv injection during operation and subsequently received TCB-2 (selective 5-HT2AR agonist, 5 μg/μL) and vi) AD+TCB-2+NAD-299 group, which received STZ via icv injection during operation and subsequently received TCB-2 (5 μg/0.5 μL) and NAD-299 (5 μg/0.5 μL). All of treatments, (TCB-2, NAD-299 and vehicle) were done via icv injection for 35 days. Figure 1 shows a schematic of experimental design and the timeline.

**Surgical Procedures**

The animals were anesthetised with ketamine (100 mg/kg, Behbod Darou, Iran) and xylazine (10 mg/kg, Alfasan, The Netherlands) and placed in a stereotaxic apparatus (Stoelting Co., Chicago, IL). The head positioned in a frame and a midline sagittal incision was made in the scalp. A guide cannula was lowered into the right lateral ventricle using the following coordinates: −0.9 mm posterior to the bregma, 1.6 mm lateral to the sagittal suture, and 3.1 mm beneath the skull (54). The guide cannula was secured for icv injection. After surgery procedure, the rats were recovery for one week. Seven days’ recovery prevented inflammatory reaction in rats. For an overview of the experimental protocol and timeline, see Figure 1.

To create AD model, STZ was dissolved in 0.9% saline, then immediately divided into aliquots and stored at −20 °C before use. STZ microinjected icv after 7 days of recovery (day 1) and again 2 days later via a cannula (day 3) at a dose of 3 mg/kg in 10 μL (34, 55, 56). After STZ microinjection, animals were icv treated NAD-299, TCB-2 or vehicle for 35 consecutive days. Drugs or vehicle microinjections were performed with a 30-G injector cannula (1 mm below the tip of the guide cannula) with a Hamilton syringe (Hamilton, Bonaduz, Switzerland) attached to the injector cannula by polyethylene micro-tubing (PE-20). Figure 2 shows the positioning of the treatment cannulas and the STZ, NAD-299, TCB-2 and saline injection.

**Figure 1.** Time line of experimental design
Protective effects of 5-HT1A receptor inhibition

Tissue Preparation

At the end of treatment, all the animals were anesthetised with ketamine and xylazine (100:10 mg/kg), transcardially perfused with 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.3) and their brains were dissected out (Figure 1). Isolated rat brain was fixed into 4% paraformaldehyde for 1 week and brains were dipped into paraffin. The brain sliced into 5 μm tissue sections using a microtome (LeitzGmBH, Wetzlar, Germany). The hippocampi were sectioned into 5 μm with 120 μm intervals (57).

TUNEL Staining: Determination of Neuronal Apoptosis

To identify apoptotic cell death in the hippocampal neurons, TUNEL staining was performed using the kit (Roch, Germany) according to the manufacturer’s instructions. The average apoptotic cell number was prepared for DNA fragmentation detection using the assay, as previously described (58). According to Paxinos and Watson (54) the coordinates for analysing the CA1 hippocampal region are −3.3 to −3.8 from Bregma, similar as previously described study (59). In brief, after sample permeabilisation (0.1 M citrate buffer, pH 6), sections were incubated with TUNEL reaction mixture for 60 min at 37 °C. Following this, converter-peroxidase (30 min) and 3,3’-diaminobenzidine substrate (10 min) were added to the samples, in that order. Sections were counterstained for hematoxylin. Mounted sections were photographed with a digital camera attached to a light microscope (400×) and number of the brown dark cells was counted. For each animal, the mean apoptotic cell number was obtained by counting five coronal sections.

Statistical Analysis

The data were analysed with one-way analysis of variance (ANOVA) and Tukey post-hoc tests. Statistical significance was set at $P < 0.05$. The data are expressed as mean ± standard deviation.

Results

Immunohistochemistry for apoptotic neurons in the CA1 region of the hippocampal coronal sections was showing in Figure 3 (a–f). TUNEL staining was further performed in these sections to detect apoptotic neurons. Table 1 presented number of apoptotic neurons for CA1 area of the hippocampus in all groups. One-way ANOVA has detected a significant difference in the number of apoptotic cells in the CA1 region between experimental groups $[F(5,35) = 174.06, P < 0.001]$ (Figure 4). Tukey post-hoc analysis revealed a higher number of apoptotic neurons in the STZ group, than in the control, sham and STZ treated with NAD-299, TCB-2 and NAD+TCB groups, respectively ($P < 0.001$). These results showed a significant reduction in apoptotic neurons in the STZ group treated with NAD+TCB and STZ rats treated with TCB-2 when compared with the NAD-299 group ($P < 0.001$ and $P < 0.003$, respectively).

Figure 2. Illustration of rat brain section. The approximate location of STZ, NAD-299, TCB-2 or saline icv injection in a cross section view of atlas plate
STZ in the hippocampus of AD rat. Treatment with NAD-299 (selective, high affinity 5-HT1AR antagonist), TCB-2 (potent, high affinity 5-HT2AR agonist), and NAD-299+TCB-2 in rats receiving STZ, decreased the neuronal apoptosis in the hippocampus area. Hippocampus has a critical role on the learning and memory (60). Synaptic plasticity in the hippocampal neurons involves in the memory formation (4). Several agents as well as neurotransmitters such cholinergic, glutamatergic, serotonergic, GABAergic, vanilloid, cannabinoid systems influence the hippocampal synaptic plasticity and learning and memory (3, 60, 61). In the AD, memory impairments are due to the hippocampal neurodegeneration, imbalance of neurotransmitter systems and apoptosis in neurons (14, 62, 63).

Also, the number of apoptotic cells was significantly lower in the STZ group treated with NAD+TCB than in the untreated STZ group ($P < 0.001$). Tukey post-hoc analysis showed that number of apoptotic neurons increased in the STZ treated with NAD-299 and TCB-2 groups compare to sham group ($P < 0.001; P < 0.003$, respectively). The apoptotic cell numbers were not significantly different between control and sham groups ($P = 0.969 < 0.050$).

**Discussion**

The present study evaluated the effects of 5-HT1AR inhibition and 5-HT2AR activation by selective antagonist and agonist in a rat model of AD. The result of current study showed that neuronal apoptosis induced by icv injection of STZ in the hippocampus of AD rat. Treatment with NAD-299 (selective, high affinity 5-HT1AR antagonist), TCB-2 (potent, high affinity 5-HT2AR agonist), and NAD-299+TCB-2 in rats receiving STZ, decreased the neuronal apoptosis in the hippocampus area.

**Table 1.** Number of apoptotic neurons for CA1 area of the hippocampus

| Group       | Control | Sham | STZ  | STZ+NAD | STZ+TCB | STZ+NAD+TCB |
|-------------|---------|------|------|---------|---------|-------------|
| Mean        | 253.16  | 218.5| 83.3 | 132.66  | 153.83  | 148.83      |
| SEM         | 6.46    | 15.39| 6.18 | 7.03    | 5.85    | 6.18        |
| SDM         | 15.82   | 37.708| 15.13| 17.23   | 14.34   | 15.14       |

standard error mean (SEM), standard deviation mean (SDM)
Protective effects of 5-HT1A receptor inhibition indicated that 5-HT1A receptor stimulates both anti-apoptotic and pro-apoptotic pathways in hamster ovary fibroblast cells (43). Stimulation of 5-HT1AR in the dorsal raphe counteracts the effect of intrahippocampal 7-chloro-kynurenic acid micro-injection on pyramidal cells in the hippocampus (44). Upregulation of 5-HT1AR by the non-selective 5-HT1AR agonist, 8-OH-DPAT alleviates cellular apoptosis, and downregulation of 5-HT1AR mediated the apoptosis pathway in the hippocampus of mouse brain (75).

The 5-HT1AR is highly expressed in the hippocampus (2, 33). This receptor is related to inhibitory Gi-proteins and 5-HT1AR function results in an inhibition of adenylyl cyclase’s activity and thus decrease the cAMP production (76). Binding of antagonists to 5-HT1AR cause disinhibitory effect of 5-HT (77, 78), and increase the activity of serotonergic neurons (79).

Hippocampal 5-HT1AR expression changed in AD, and molecular binding to 5-HT1AR has been examined in AD patients (46). Present finding showed that NAD-299, selective 5-HT1AR antagonist decreased the neuronal apoptosis in hippocampus. Also, this study confirmed the previous suggestion about selective agonist for 5-HT1AR and new therapeutic target in nervous disorders (39) and it is demonstrated that Aβ injected in rat hippocampus induced over expression of 5-HT1AR a rat model of AD (46).

The present study revealed that icv injection of NAD-299 diminished the effect of STZ-induced neuronal apoptosis in the hippocampus. 5-HT1AR protein expressions decreased neuronal death of astrocytes in the ischemic hippocampal CA1 region (74). In agreement with current results, amyloid beta peptide induced neuronal death and decreased expression of 5-HT1AR in rat brain (46). Another study indicated that 5-HT1A receptor stimulates both of anti-apoptotic and pro-apoptotic pathways in hamster ovary fibroblast cells (43). Stimulation of 5-HT1AR in the dorsal raphe counteracts the effect of intrahippocampal 7-chloro-kynurenic acid micro-injection on pyramidal cells in the hippocampus (44). Upregulation of 5-HT1AR by the non-selective 5-HT1AR agonist, 8-OH-DPAT alleviates cellular apoptosis, and downregulation of 5-HT1AR mediated the apoptosis pathway in the hippocampus of mouse brain (75).

The 5-HT1AR is highly expressed in the hippocampus (2, 33). This receptor is related to inhibitory Gi-proteins and 5-HT1AR function result in an inhibition of adenylyl cyclase’s activity and thus decrease the cAMP production (76). Binding of antagonists to 5-HT1AR cause disinhibitory effect of 5-HT (77, 78), and increase the activity of serotonergic neurons (79). Hippocampal 5-HT1AR expression changed in AD, and molecular binding to 5-HT1AR has been examined in AD patients (46). Present finding showed that NAD-299, selective 5-HT1AR antagonist decreased the neuronal apoptosis in hippocampus. Also, this study confirmed the previous suggestion about selective agonist for 5-HT1AR and new therapeutic target in nervous disorders (39) and it is demonstrated that Aβ injected in rat hippocampus induced over expression of 5-HT1AR a rat model of AD (46).
The other finding of current study showed that icv administration of TCB-2, potent and high affinity 5-HT2AR agonist, reduced STZ-induced apoptosis in the hippocampus. 5-HT2AR has high expression in the hippocampus (33). The expression of 5-HT2AR mRNA in granule cells and pyramidal neurons of hippocampus have been demonstrated in clinical and pre-clinical cellular studies (80, 81). TCB-2 binding to the 5-HT2AR is linked to Gq-proteins and exert its effect via the phospholipase-C signaling pathway (74), and 5-HT2AR activity prevents apoptosis of cell (46). Therefore, it seems that, chronic icv administration of TCB-2 decreased the apoptosis in neurons of hippocampus.

Current result indicated that treatment with NAD-299+TCB-2 inhibited the apoptosis effect of icv-STZ in the hippocampus of rat. It seems that blockade of 5-HT1AR and the activation of 5-HT2AR can potentiate the valuable, and single effect of NAD-299 or TCB-2 in neurons of hippocampus. There are few available studies about synergetic effect of these receptors and apoptosis in the nervous system. Both of these receptors have the remarkable expression of mRNA in the hippocampus (81). Combined treatment with NAD-299 and TCB-2 begin phospholipase-C signaling pathway, and reinforce the influence of serotonin in serotonergic neurons (77–79). The technique or agent which can modulate the death of a cell is known for therapeutic target in neurodegenerative disease (21). Therefore, current finding showed that the combined treatment with NAD-299 and TCB-2 has a synergetic effect in the brain and the apoptosis neuron is decreased in the hippocampus of rats.

There are some limitations in the current study. One of the limitations is other assays support the results of TUNEL assay in order to differentiate the cell necrosis from neuronal apoptosis in this study. Also, the result of current study is completed, if the control with NAD-299 and TCB-2 treated without icv-STZ injection is added in experimental groups. The other limitation of this finding was the treatment doses of TCB-2 and NAD-299. There was no significant difference in STZ+TCB-2 compared to STZ+NAD+TCB. Synergistic effect of 5-HT1AR inhibition and 5-HT2AR stimulation was found compared to 5-HT1AR blocking. It is possible that findings were completed by different doses of agent. The more research is necessary for better understanding about the beneficial effect of synergic treatment of these receptors in the central nervous system.

Conclusion

In conclusion, the present study demonstrates that 35 days icv administration of NAD-299 and TCB-2 prevented the STZ-induced apoptosis in the hippocampus of rat received icv-STZ. The combine treatment with NAD-299 and TCB-2 has a synergetic effect in the hippocampus.

Acknowledgements

This work was supported by a grant (grant number: 9512177927) and facilities from the Neurophysiology Research Centre, Hamadan University of Medical Sciences, Iran.

Ethics of Study

All experiments were approved by the research and ethics committees of the Hamadan University of Medical Sciences (IR.UMSHA.REC.1395.547) and were performed according to the Guide for Care and Use of Laboratory Animals published by the United States National Institutes of Health (NIH Publication No. 85-23, revised 1985).

Conflict of Interest

None.

Funds

This work was supported by a grant number 9512177927 of Hamadan University of Medical Sciences, Iran.

Authors’ Contributions

Conception and design: SS, NH-F, SA, SSA
Analysis and interpretation of the data: NH-F, SA, SSA
Drafting of the article: SS, NH-F, SA, SSA, AK
Critical revision of the article for important intellectual content: SS, NH-F
Final approval of the article: SS, NH-F, SA, AK
Provision of study materials or patients: NH-F
Statistical expertise: NH-F
Obtaining of funding: SS, NH-F
Administrative, technical, or logistic support: AK
Collection and assembly of data: NH-F, SA
Original Article | Protective effects of 5-HT1A receptor inhibition

Correspondence

Dr Nasrin Hashemi-Firouzi
PhD (Hamadan University of Medical Sciences, Iran)
Neurophysiology Research Center,
Hamadan University of Medical Sciences,
Hamadan, Iran.
Tel: +98 8138380462
Fax: +98 8138380208
E-mail: nhashemifirozi@yahoo.com

References

1. Claeyssen S, Bockaert JI, Giannoni P. Serotonin: a new hope in Alzheimer’s disease? ACS Chem Neurosci. 2015;6(7):940–943. https://doi.org/10.1021/acscchemneuro.5b00135

2. Verdurand M, Zimmer L. Hippocampal 5-HT1A receptor expression changes in prodromal stages of Alzheimer’s disease: beneficial or deleterious? Neuropharmacology. 2017;123:446–454. https://doi.org/10.1016/j.neuropharm.2017.06.021

3. Shahidi S, Soleimani Asl S, Komaki A, Hashemi-Firouzi N. The effect of chronic stimulation of serotonin receptor type 7 on recognition, passive avoidance memory, hippocampal long-term potentiation, and neuronal apoptosis in the amyloid β protein treated rat. Psychopharmacology. 2018;235(5):1513–1525. https://doi.org/10.1007/s00213-018-4862-3

4. Zargooshnia S, Shahidi S, Ghahremanitamadon F, Nikkhah A, Mehdizadeh M, Soleimani Asl S. The protective effect of Borago officinalis extract on amyloid beta(25-35)-induced long term potentiation disruption in the dentate gyrus of male rats. Metab. Brain Dis. 2015;30(1):151–156. https://doi.org/10.1007/s11011-014-9594-4

5. Devanand D, Bansal R, Liu J, Hao X, Pradhaban G, Peterson BS. MRI hippocampal and entorhinal cortex mapping in predicting conversion to Alzheimer’s disease. Neuroimage. 2012;60(3):1622–1629. https://doi.org/10.1016/j.neuroimage.2012.01.075

6. Diikav V, Anand K. Potential predictors of hippocampal atrophy in Alzheimer’s disease. Drugs Aging. 2011;28(1):1–11. https://doi.org/10.2165/11586390-00000000-00000

7. Li S, Shi F, Pu F, Li X, Jiang T, Xie S, et al. Hippocampal shape analysis of Alzheimer disease based on machine learning methods. AJNR Am J Neuroradiol. 2007;28(7):1339–1345. https://doi.org/10.3174/ajnr.A0620

8. Tsang SW, Keene J, Hope T, Spence I, Francis PT, Wong PT-H, et al. A serotoninergic basis for hyperphagic eating changes in Alzheimer’s disease. J Neurol Sci. 2010;288(1–2):151–155. https://doi.org/10.1016/j.jns.2009.08.066

9. Butterfield DA, Boyd-Kimball D. Amyloid β-peptide(1-42) contributes to the oxidative stress and neurodegeneration found in Alzheimer disease brain. Brain Pathol. 2004;14(4):426–432. https://doi.org/10.1111/j.1750-3639.2004.tb00087.x

10. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, et al. Dendritic function of tau mediates amyloid-β toxicity in Alzheimer’s disease mouse models. Cell. 2010;142(3):387–397. https://doi.org/10.1016/j.cell.2010.06.036

11. Takashima A. Amyloid-β, tau, and dementia. J Alzheimers Dis. 2009;17(4):729–736. https://doi.org/10.3233/JAD-2009-1090

12. Kumar A, Singh A, Ekavali. A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacol Rep. 2015;67(2):195–203. https://doi.org/10.1016/j.pharep.2014.09.004

13. Overk CR, Masliah E. Pathogenesis of synaptic degeneration in Alzheimer’s disease and Lewy body disease. Biochem Pharmacol. 2014;88(4):508–516. https://doi.org/10.1016/j.bcp.2014.01.015

14. Hashemi-Firouzi N, Komaki A, Soleimani Asl S, Shahidi S. The effects of the 5-HT7 receptor on hippocampal long-term potentiation and apoptosis in a rat model of Alzheimer’s disease. Brain Res Bull. 2017;135:85–91. https://doi.org/10.1016/j.brainresbull.2017.10.004

15. Eckert A, Keil U, Marques CA, Bonert A, Frey C, Schüssel K, et al. Mitochondrial dysfunction, apoptotic cell death, and Alzheimer’s disease. Biochem Pharmacol. 2003;66(8):1627–1634. https://doi.org/10.1016/S0006-2952(03)00534-3
16. Ghahremanitamadon F, Shahidi S, Zargooshnia S, Nikkhah A, Ranjar A, Soleimani Asl S. Protective effects of *Borago officinalis* extract on amyloid beta-peptide(25-35)-induced memory impairment in male rats: a behavioral study. *Biomed Res Int*. 2014;2014:1–8. https://doi.org/10.1155/2014/798535

17. Park S, Lee J-H, Yang EJ. Effects of Acupuncture on Alzheimer’s Disease in Animal-Based Research. *Evid Based Complement Alternat Med*. 2017;2017:1–5. https://doi.org/10.1155/2014/798535.10.155/2017/6512520

18. Arora RB, Kumar K, Deshmukh RR. FK506 attenuates intracerebroventricular streptozotocin-induced neurotoxicity in rats. *Behav Pharmacol*. 2013;24(7):580–589. https://doi.org/10.1097/ FBP.0b013e32836546db

19. Grieb P. Intracerebroventricular streptozotocin injections as a model of Alzheimer’s disease: in search of a relevant mechanism. *Mol Neurobiol*. 2016;53(3):1741–1752. https://doi.org/10.1007/s12035-015-9132-3

20. Ravelli KG, dos Anjos Rosário B, Camarin R, Hernandes MS, Britto LR. Intracerebroventricular streptozotocin as a model of Alzheimer’s disease: neurochemical and behavioral characterization in mice. *Neurotox Res*. 2017;31(3):327–333. https://doi.org/10.1007/s12640-016-9684-7

21. Elmore S. Apoptosis: a review of programmed cell death. *Toxicol Pathol*. 2007;35(4):495–516. https://doi.org/10.1080/01926230701320337

22. Salkovic-Petrisic M, Osmanovic-Barilar J, Bruckner MK, Hoyer S, Arendt T, Riederer P. Cerebral amyloid angiopathy in streptozotocin rat model of sporadic Alzheimer’s disease: a long-term follow up study. *J Neural Transm (Vienna)*. 2011;118(5):765–772. https://doi.org/10.1007/s00702-011-0651-4

23. Majkutewicz I, Kurowska E, Podlacha M, Myślińska D, Grembecka B, Ruciński J, et al. Dimethyl fumarate attenuates intracerebroventricular streptozotocin-induced spatial memory impairment and hippocampal neurodegeneration in rats. *Behav Brain Res*. 2016;308:24–37. https://doi.org/10.1016/j.bbr.2016.04.012

24. Fan LL, Zhang QJ, Liu J, Feng J, Gui ZH, Ali U, et al. In vivo effect of 5-HT7 receptor agonist on pyramidal neurons in medial frontal cortex of normal and 6-hydroxydopamine-lesioned rats: an electrophysiological study. *Neuroscience*. 2011;190:328–338. https://doi.org/10.1016/j.neuroscience.2011.06.011

25. Kamat PK, Kalani A, Rai S, Tota SK, Kumar A, Ahmad AS. Streptozotocin intracerebroventricular-induced neurotoxicity and brain insulin resistance: a therapeutic intervention for treatment of sporadic Alzheimer’s disease (SAD)-like pathology. *Mol Neurobiol*. 2016;53(7):4548–4562. https://doi.org/10.1007/s12035-015-9384-y

26. Labak M, Foniok T, Kirk D, Rushforth D, Tomanek B, Jasiński A, et al. Metabolic changes in rat brain following intracerebroventricular injections of streptozotocin: a model of sporadic Alzheimer’s disease. *Acta Neurochir Suppl*. 2010;106:177–181. https://doi.org/10.1007/978-3-211-98811-4_32

27. Ghavami S, Shojaei S, Yeganeh B, Ande SR, Jangamreddy JR, Mehrpour M, et al. Autophagy and apoptosis dysfunction in neurodegenerative disorders. *Prog Neurobiol*. 2014;112:24–49. https://doi.org/10.1016/j.pneurobio.2013.10.004

28. Hashemi-Firouzi N, Shahidi S, Soleimani-Asl S, Komaki A. 5-Hydroxytryptamine receptor 6 antagonist, SB258585 exerts neuroprotection in a rat model of Streptozotocin-induced Alzheimer’s disease. *Metab Brain Dis*. 2018;33(4):1243–1253. https://doi.org/10.1007/s11011-018-0228-0

29. He B, Lu N, Zhou Z. Cellular and nuclear degradation during apoptosis. *Curr Opin Cell Biol*. 2009;21(6):900–912. https://doi.org/10.1016/j.jceb.2009.08.008

30. Caccamo A, Branca C, Piras IS, Ferreira E, Huentelman MJ, Liang WS, et al. Necroptosis activation in Alzheimer’s disease. *Nat Neurosci*. 2017;20(9):1236–1246. https://doi.org/10.1038/nn.4608

31. Shimohama S. Apoptosis in Alzheimer’s disease—a update. *Apoptosis*. 2000;5(1):9–16.

32. Almasi A, Zarei M, Raoufi S, Sarihi A, Salehi I, Komaki A, et al. Influence of hippocampal GABAB receptor inhibition on memory in rats with acute beta-amyloid toxicity. *Metab Brain Dis*. 2018;33(6):1859–1867. https://doi.org/10.1007/s11011-018-0292-5
33. Berumen LC, Rodriguez A, Miledi R, Garcia-Alcocer G. Serotonin receptors in hippocampus. ScientificWorldJournal. 2012;2012:1–15. https://doi.org/10.1100/2012/823493

34. Stiedl O, Pappa E, Konradsson-Geuken Å, Ögren SO. The role of the serotonin receptor subtypes 5-HT1A and 5-HT7 and its interaction in emotional learning and memory. Front Pharmacol. 2015;6:162. https://doi.org/10.3389/fphar.2015.00162. eCollection 2015

35. Shahidi S, Hashemi-Firouzi N. Role of 5-HT7 receptors in the anxiety-like behavior in nalozone-induced withdrawal symptoms in mice. Neurochemical Journal. 2013;7(4):308–312. https://doi.org/10.1134/S1819712413040107

36. Shahidi S, Hashemi-Firouzi N. The effects of a 5-HT7 receptor agonist and antagonist on morphine withdrawal syndrome in mice. Neurosci Lett. 2014;578:27–32. https://doi.org/10.1016/j.neulet.2014.06.027

37. Shahidi S, Bathaei A, Pahlevani P. Antinociceptive effects of Valeriana extract in mice: involvement of the dopaminergic and serotonergic systems. Neurophysiology. 2013;45(5–6):448–452. https://doi.org/10.1007/s11062-013-9392-3

38. Ramírez-Rodriguez G, Ortiz-López L, Domínguez-Alonso A, Benítez-King GA, Kempermann G. Chronic treatment with melatonin stimulates dendrite maturation and complexity in adult hippocampal neurogenesis of mice. J Pineal Res. 2011;50(1):29–37. https://doi.org/10.1111/j.1600-079x.2010.00802.x

39. Meneses A, Perez-Garcia G. 5-HT1A receptors and memory. Neurosci Biobehav Rev. 2007;31(5):705–727. https://doi.org/10.1016/j.neubiorev.2007.02.001

40. McCory JD, Roth BL. Structure and function of serotonin G protein-coupled receptors. Pharmacol Ther. 2015;150:129–142. https://doi.org/10.1016/j.pharmthera.2015.01.009

41. King MV, Marsden CA, Fone KC. A role for the 5-HT1A, 5-HT4 and 5-HT6 receptors in learning and memory. Trends Pharmacol Sci. 2008;29(9):482–492. https://doi.org/10.1016/j.tips.2008.07.001

42. Banasz M, Hery M, Printemps R, Daszuta A. Serotonin-induced increases in adult cell proliferation and neurogenesis are mediated through different and common 5-HT receptor subtypes in the dentate gyrus and the subventricular zone. Neuropsychopharmacology. 2004;29(3):450–460. https://doi.org/10.1038/sj.npp.1300320

43. Turner JH, Garnovskaya MN, Raymond JR. Serotonin 5-HT1A receptor stimulates c-Jun N-terminal kinase and induces apoptosis in Chinese hamster ovary fibroblasts. Biochim Biophys Acta. 2007;1773(3):391–399. https://doi.org/10.1016/j.bbamcr.2006.12.003

44. Carli M, Balducci C, Samanin R. Stimulation of 5-HT1A receptors in the dorsal raphe ameliorates the impairment of spatial learning caused by intrahippocampal 7-chloro-kynurenic acid in naive and pretrained rats. Psychopharmacology. 2001;158(1):39–47. https://doi.org/10.1007/s002130100

45. Ögren SO, Eriksson TM, Elvander-Tottie E, D’Addario C, Ekström JC, Svenningsson P, et al. The role of 5-HT1A receptors in learning and memory. Behav Brain Res. 2008;195(1):54–77. https://doi.org/10.1016/j.bbr.2008.02.023

46. Verdurand M, Chauveau F, Daoust A, Morel A-L, Bonnefoi F, Liger F, et al. Differential effects of amyloid-beta 1–40 and 1–42 fibrils on 5-HT1A serotonin receptors in rat brain. Neurobiol Aging. 2016;40:11–21. https://doi.org/10.1016/j.neurobiolaging.2015.12.008

47. Zhang G, Stackman Jr RW. The role of serotonin 5-HT2A receptors in memory and cognition. Front Pharmacol. 2015;6:225. https://doi.org/10.3389/fphar.2015.00225

48. Afshar S, Shahidi S, Rohani AH, Komaki A, Asl SS. The effect of NAD-299 and TCB-2 on learning and memory, hippocampal BDNF levels and amyloid plaques in Streptozotocin-induced memory deficits in male rats. Psychopharmacology (Berl). 2018;235(10):2809–2822. https://doi.org/10.1007/s00213-018-4973-x

49. Kulesza Jr RJ. Cytoarchitecture of the human superior olivary complex: nuclei of the trapezoid body and posterior tier. Hear Res. 2008;241(1–2):52–63. https://doi.org/10.1016/j.heares.2008.04.010
50. Krichevsky AM, Kosik KS. RNAi functions in cultured mammalian neurons. Proc Natl Acad Sci USA. 2002;99(18):11926–11929. https://doi.org/10.1073/pnas.182272699

51. Scott J, Willett IH. Binding of cationic dyes to nucleic acids and other biological polyanions. Nature. 1966;209(5027):985–987. https://doi.org/10.1038/209985ao.

52. Kádár A, Wittmann G, Liposits Z, Fekete C. Improved method for combination of immunocytochemistry and Nissl staining. J Neurosci Methods. 2009;184(1):115–118. https://doi.org/10.1016/j.jneumeth.2009.07.010

53. Anderson AJ, Stoltzner S, Lai F, Su J, Nixon RA. Morphological and biochemical assessment of DNA damage and apoptosis in Down syndrome and Alzheimer disease, and effect of postmortem tissue archival on TUNEL. Neurobiol Aging. 2000;21(4):511–524. https://doi.org/10.1016/S0197-4580(00)00126-3

54. Paxinos G, CharlesW. The rat brain in stereotaxic coordinates. 6th ed. Amsterdam: Academic Press; 2017.

55. Shonesy BC, Thiruchelvam K, Parameswaran K, Rahman EA, Karuppagounder SS, Huggins KW, et al. Central insulin resistance and synaptic dysfunction in intracerebroventricular-streptozotocin injected rodents. Neurobiol Aging. 2012;33(2):430.e5–430.e18. https://doi.org/10.1016/j.neurobiolaging.2010.12.002

56. Hoyer S, Lannert H. Long-term abnormalities in brain glucose/energy metabolism after inhibition of the neuronal insulin receptor: implication of tau-protein. J Neural Transm Suppl. 2007;72:195–202. https://doi.org/10.1007/978-3-211-73574-9_25

57. Soleimani Asl S, Mousavizadeh K, Pourheydar B, Soleimani M, Rahbar E, Meh dizadeh M. Protective effects of N-acetylcy steine on 3,4-methylenedioxym ethamphetamine-induced neurotoxicity in male Sprague-Dawley rats. Metab Brain Dis. 2013;28(4):677–686. https://doi.org/10.1007/s11011-013-9423-1

58. Pourheydar B, Soleimani Asl S, Azinm zadeh M, Rezaei Moghadam A, Marzban A, Meh dizadeh M. Neuroprotective effects of bone marrow mesenchymal stem cells on bilateral common carotid arteries occlusion model of cerebral ischemia in rat. Behav Neurol. 2016;2016:1–10. https://doi.org/10.1155/2016/2964712

59. Azad N, Rasoolijazi H, Joghataie MT, Soleimani S. Neuroprotective effects of carnosic Acid in an experimental model of Alzheimer's disease in rats. Cell J. 2011;13(1):39–44.

60. Beigi B, Shahidi S, Komaki A, Sarihi A, Hashemi- Firouzi N. Pretraining hippocampal stimulation of melatonin type 2 receptors can improve memory acquisition in rats. Int J Neurosci. 2018;15:1–9. https://doi.org/10.1080/00207454.2018.1545770

61. Tahmasebi L, Komaki A, Karamian R, Shahidi S, Sarihi A, Komaki H. Interaction between paired-pulse facilitation and long-term potentiation during the stimulation of the cannabinoid and vanilloid systems in the dentate gyrus. Brain Res. 2016;1643:27–34. https://doi.org/10.1016/j.brainres.2016.04.058

62. Mattson MP. Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol. 2000;1(2):120–129. https://doi.org/10.1038/35040009

63. LeBlanc AC. The role of apoptotic pathways in Alzheimer's disease neurodegeneration and cell death. Curr Alzheimer Res. 2005;2(4):389–402. https://doi.org/10.2174/156720505774330573

64. Rai S, Kamat PK, Nath C, Shukla R. Glial activation and post-synaptic neurotoxicity: the key events in streptozotocin (ICV) induced memory impairment in rats. Pharmacol Biochem Behav. 2010;117:104–117. https://doi.org/10.1016/j.pbb.2013.11.035

65. Doonan F, Cotter TG. Detection of DNA fragmentation in retinal apoptosis by TUNEL. Methods Mol Biol. 2013;935:207–213. https://doi.org/10.1007/978-1-62703-080-9_14

66. Kim S-E, Ko I-G, Kim B-K, Shin M-S, Cho S, Kim C-J, et al. Treadmill exercise prevents aging-induced failure of memory through an increase in neurogenesis and suppression of apoptosis in rat hippocampus. Exp Gerontol. 2010;45(5):357–365. https://doi.org/10.1016/j.exger.2010.02.005

67. Chen Y, Tian Z, Liang Z, Sun S, Dai C-l, Lee MH, et al. Brain gene expression of a sporadic (icv-STZ Mouse) and a familial mouse model (3xTg-AD mouse) of Alzheimer’s disease. PLoS One. 2012;7(12):1–12. https://doi.org/10.1371/journal.pone.0051432
68. Unsal C, Oran M, Albayrak Y, Aktas C, Erboga M, Topcu B, et al. Neuroprotective effect of ebselen against intracerebroventricular streptozotocin-induced neuronal apoptosis and oxidative stress in rats. *Toxicol Ind Health*. 2016;32(4):730–440. https://doi.org/10.1177/07482371359429

69. Gavieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. *J Cell Biol*. 1992;119(3):493–501. https://doi.org/10.1083/jcb.119.3.493.

70. Biswas J, Goswami P, Gupta S, Joshi N, Nath C, Singh S. Streptozotocin induced neurotoxicity involves Alzheimer’s related pathological markers: a study on N2a cells. *Mol Neurobiol*. 2016;53(5):2794–2806. https://doi.org/10.1007/s12035-015-9144-z

71. Guo X-d, Sun G-l, Zhou T-t, Wang Y-y, Xu X, Shi X-f, et al. LX2343 alleviates cognitive impairments in AD model rats by inhibiting oxidative stress-induced neuronal apoptosis and tauopathy. *Acta Pharmacol Sin*. 2017;38(8):1104–1119. https://doi.org/10.1038/aps.2016.128

72. Salkovic-Petrisic M, Knezovic A, Osmanovic-Barilar J, Smajlovic U, Trkulja V, Riederer P, et al. Multi-target iron-chelators improve memory loss in a rat model of sporadic Alzheimer’s disease. *Life Sci*. 2015;136:108–119. https://doi.org/10.1016/j.lfs.2015.06.026

73. Schmid CL, Bohn LM. Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ss-arrestin2Src/Akt signaling complex in vivo. *J Neurosci*. 2010;30(40):13513–13524. https://doi.org/10.1523/JNEUROSCI.1665-10.2010

74. Lee CH, Ahn JH, Won M-H. New expression of 5-HT1A receptor in astrocytes in the gerbil hippocampal CA1 region following transient global cerebral ischemia. *Neuril Sci*. 2015;36(3):383–389. https://doi.org/10.1007/s10072-014-1958-3

75. Ping F, Shang J, Zhou J, Zhang H, Zhang L. 5-HT1A receptor and apoptosis contribute to interferon-α-induced “depressive-like” behavior in mice. *Neurosci Lett*. 2012;514(2):173–178. https://doi.org/10.1016/j.neulet.2012.02.087

76. Raymond JR, Mukhin YV, Gettys TW, Garnovskaya MN. The recombinant 5-HT1A receptor: G protein coupling and signalling pathways. *Br J Pharmacol*. 1999;127(8):1751–1764. https://doi.org/10.1038/sj.bjp.0702723

77. Blier P, De Montigny C. Current advances and trends in the treatment of depression. *Trends Pharmacol Sci*. 1994;15(7):220–226. https://doi.org/10.1016/0165-6147(94)90315-8

78. Forster EA, Cliffe IA, Bill DJ, Dover GM, Jones D, Reilly Y, et al. A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635. *Eur J Pharmacol*. 1995;281(1):81–88. https://doi.org/10.1016/0014-2999(95)00234-C

79. Jacobs BL, Martín-Cora FJ, Fornal CA. Activity of medullary serotonergic neurons in freely moving animals. *Brain Res Rev*. 2002;40(1–3):45–52. https://doi.org/10.1016/S0165-0173(02)00187-X.

80. Palacios JM. Serotonin receptors in brain revisited. *Brain Res*. 2016;1645:46–49. https://doi.org/10.1016/j.brainres.2015.12.042

81. Burnet P, Eastwood S, Lacey K, Harrison P. The distribution of 5-HT1A and 5-HT2A receptor mRNA in human brain. *Brain Res*. 1995;676(1):157–168. https://doi.org/10.1016/0006-8993(95)00104-X